



Updated Monthly

February 9, 2022

---

THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:





## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

  @G2Gconsulting





<https://www.g2gconsulting.com/gbg-reporting-service/>

# GBG Report

*Updated Monthly*

February 9, 2022

## Table of Contents

Air Force Office of Scientific Research .....	1	Maternal and Pediatric Health .....	24
Air Force Research Laboratory.....	2	Medical Countermeasures.....	26
Army Applications Lab.....	2	Mental Health.....	26
Army Research Laboratory.....	2	National Science Foundation.....	28
Army Research Office .....	3	National Virtual Biotechnology Laboratory.....	28
Artificial Intelligence & Machine Learning.....	3	Office of Naval Research .....	28
BARDA .....	4	Orthotics and Prosthetics.....	29
Biomedical Research.....	4	Pain Management.....	29
Cancer .....	5	Patient-Centered Research.....	30
Cardiovascular and Pulmonary Health.....	9	Rare Diseases .....	31
Chronic Pain.....	11	Small Business Development .....	31
Cognitive and Brain Health.....	11	Substance Use Disorder.....	32
Coronavirus .....	14	Therapeutics.....	37
DARPA .....	16	Translational Science .....	38
Diagnostics .....	17	Tuberous Sclerosis Complex .....	38
Disabilities.....	18	US Air Force Academy .....	39
Endocrine and Metabolic Diseases .....	18	US Army Combat Capabilities Development Command.....	39
Energy Science .....	19	US Army Research Institute .....	39
Environmental Health.....	19	US Military Academy.....	40
Genomics.....	19	US Navy .....	40
Global Health.....	20	USAMRDC Extramural BAA .....	41
Health IT .....	20	USSOCOM Extramural R&D.....	42
HIV/AIDS .....	22	Warfighter Medical Optimization Division .....	42
Immunology & Infectious Disease .....	23		





<https://www.g2gconsulting.com/gbg-reporting-service/>

## GBG Report

**Updated Monthly**

February 9, 2022

**February 18, 2022** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE and open to all) when we will take a closer look at funding opportunities listed below and close with Q&A. Click [here](#) to register. Then from 10:30-11am EST (G2G and GBG customers) non-dilutive funding consultation for GBG customers, G2G clients and members of state BIO chapters and organizations who are clients of G2G.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
<b>AIR FORCE OFFICE OF SCIENTIFIC RESEARCH (2)</b>						
1.	Air Force Office of Scientific Research Broad Agency Announcement (DoD/Air Force)	FA9550-18-S-0003	This BAA’s focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation.	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996">https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996</a>  (Full announcement in Related Documents tab)
2.	Research Interests of the Air Force Office of Scientific Research (DoD/Air Force)	FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are managed in within four teams under two scientific Departments: Engineering and Information Science & Physical and Biological Sciences. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight.	White papers accepted on a rolling basis	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084</a>  (Full announcement in Related Documents tab)



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>AIR FORCE RESEARCH LABORATORY (1)</b>			
3.	Collaborations for Innovative Research on Aerospace Structure (CIRAS) BAA (DoD/AFRL)	FA865021S 2205	The Aerospace Vehicles Division (RQV), Aerospace Systems Directorate (RQ), Air Force Research Laboratory (AFRL), is soliciting research in aircraft structural design, analysis, and experimentation, specifically in the following areas: 1. Innovative structural concepts for reducing weight and/or improving performance 2. Generation of realistic load and environmental spectra Advanced structural design and analysis methods	White papers accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=333471">https://www.grants.gov/web/grants/view-opportunity.html?oppId=333471</a>  (Full announcement in Related Documents tab)
			<b>ARMY APPLICATIONS LAB (1)</b>			
4.	Army Applications Lab BAA for Disruptive Applications (DoD/Army)	W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.	Proposals accepted through 5/1/24  Pre-proposal is required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517">https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517</a>  (Full announcement in Related Documents tab)
			<b>ARMY RESEARCH LABORATORY (1)</b>			
5.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD/Army)	W911NF-17-S-0003	The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&T Campaigns located at <a href="http://www.arl.army.mil">www.arl.army.mil</a> . These documents are subject to periodic refinements which may result in taxonomy inconsistencies.	Proposals accepted on a rolling basis until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf">https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>ARMY RESEARCH OFFICE (2)</b>			
6.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD/Army)	W911NF-17-S-0002-07	The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Technical Competencies: Computational Sciences, Ballistics Sciences, Materials & Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network & Information Sciences and Human Sciences.	Proposals accepted on a rolling basis until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf</a>
7.	Army Research Office Broad Agency Announcement Staff Research Program (DoD/Army)	W911NF20 S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.	Proposals accepted on a rolling basis until 2/19/25	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>
			<b>ARTIFICIAL INTELLIGENCE &amp; MACHINE LEARNING (2)</b>			
8.	SCiDAC): Partnership in Nuclear Physics (DoE/Office of Science)	DE-FOA-0002589	This FOA invites new research applications for the SciDAC-5 Partnerships that enable or accelerate scientific discovery, aligned with the NP mission, through productive collaborations between nuclear physicists and applied mathematicians and/or computer scientists from the SciDAC Institutes to fully exploit the capabilities of DOE HPC.	Letter of intent due: 2/24/22 Proposal due: 4/26/22	Up to \$2.75 million per year, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=337052">https://www.grants.gov/web/grants/view-opportunity.html?oppId=337052</a>
9.	Molecular Foundations for Biotechnology (MFB) (NSF)	NSF 22-554	This initiative calls for fundamentally new approaches in molecular sciences to drive new directions in biotechnology, a critical and emerging technology of the 21st century. This year's solicitation calls for synergistic scientific research collaborations that involve innovative machine learning (ML) methods to foster advances in research on the function of biomolecular systems and have the potential to drive innovation in biotechnology.	Letter of intent due: 2/14/22 Proposal due: 4/14/22	Dependent upon proposal	<a href="https://www.nsf.gov/pubs/2022/nsf22554/nsf22554.htm">https://www.nsf.gov/pubs/2022/nsf22554/nsf22554.htm</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>BARDA (2)</b>			
10.	BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA)	BAA-20-100-SOL-00002	<p>BARDA is currently accepting submissions through the EZ-BAA for several AOIs.</p> <ul style="list-style-type: none"> <li>• AOI #2: Infection Severity and Solving Sepsis.</li> <li>• AOI #5: ReDirect (Repurposing Drugs in Response to Chemical Threats).</li> <li>• AOI #8: Bringing Laboratory Testing to the Home.</li> <li>• AOI #9: Digital Health Tools for Pandemic Preparedness.</li> <li>• AOI #10: Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens.</li> <li>• AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2.</li> <li>• AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection.</li> <li>• AOI #12: Mitigating Long-term Effects (MILE) of Respiratory Distress.</li> <li>• AOI #13: Endotyping for Host-Directed Therapeutics</li> </ul>	Proposals accepted on a rolling basis until 2/3/23	Up to \$750,000 per award	<a href="https://sam.gov/opp/0f026c861ae84ef499be99d7604ef3db/view">https://sam.gov/opp/0f026c861ae84ef499be99d7604ef3db/view</a>  <a href="https://drive.hhs.gov/partner.html">https://drive.hhs.gov/partner.html</a>
11.	BARDA Broad Agency Announcement (HHS/BARDA)	BARDA BAA	BARDA is working its way through the queue of white papers that accumulated during the pandemic and were submitted on topics other than COVID-19. BARDA is still accepting proposals related to diagnostics and point of care tests for COVID and is accepting proposals on other Medical Countermeasures (MCMs) topics that include: CBRN Vaccines, Antivirals and Antitoxins; Antibacterials; Radiological, Nuclear and Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza and Emerging Infectious Diseases vaccines and therapeutics.	White papers due: 5/2/22	Dependent upon proposal	<a href="https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view">https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view</a>  <a href="https://www.medicalcountermeasures.gov/barda/barda-baa">https://www.medicalcountermeasures.gov/barda/barda-baa</a>
			<b>BIOMEDICAL RESEARCH (1)</b>			
12.	Pre-Announcement: Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed) (NIH/NIBIB)	NOT-EB-22-002	This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nation's needs in biomedical research and healthcare technologies.	<p>Estimated post date: 3/8/22</p> <p>Estimated proposal due date: 5/30/22</p>	Up to \$40,000 per year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-EB-22-002.html">https://grants.nih.gov/grants/guide/notice-files/NOT-EB-22-002.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>CANCER (34)</b>			
13.	Pre-Announcement: Ovarian Cancer Research Program (DoD/CDMRP)	N/A	<p>Seven awards are expected to be funded under OCRP. Applications submitted to the FY22 OCRP must address one or more of the following areas of emphasis:</p> <ul style="list-style-type: none"> <li>• Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics and other critical events</li> <li>• Develop novel therapeutic strategies for treatment and prevention</li> <li>• Identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis and prognosis</li> <li>• Identify and implement strategies to improve the survivorship and quality of life</li> <li>• Address health disparities</li> <li>• Address precision medicine</li> </ul>	TBD	<p>Up to \$1.5 million, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<a href="https://cdmrp.army.mil/pubs/press/2022/22ocrppreann">https://cdmrp.army.mil/pubs/press/2022/22ocrppreann</a>
14.	Pre-Announcement: Lung Cancer Research Program (DoD/CDMRP)	N/A	<p>LCRP expects to fund five awards in FY22. Applications submitted to the FY22 LCRP must address one or more of the following Areas of Emphasis:</p> <ul style="list-style-type: none"> <li>• Identify innovative strategies for the prevention of the occurrence and for the screening and early detection of lung cancer.</li> <li>• Understand the molecular mechanisms of initiation and progression and contributors to lung cancer development other than tobacco.</li> <li>• Identify innovative strategies for the treatment and prevention of recurrence of or metastases from lung cancer.</li> <li>• Develop or optimize biomarkers to assist with therapeutic decision-making.</li> <li>• Understand mechanisms of resistance to treatment.</li> <li>• Identify innovative strategies for comprehensive lung cancer care.</li> <li>• Understand factors and/or develop implementation strategies to address health disparities in lung cancer.</li> </ul>	TBD	<p>Up to \$1.2 million, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<a href="https://cdmrp.army.mil/pubs/press/2022/22lcrppreann">https://cdmrp.army.mil/pubs/press/2022/22lcrppreann</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>CANCER</b>			
15.	Pre-Announcement: Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) (NIH/NCI/ORWH)	NOT-CA-22-031	This FOA will solicit applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in low- and middle-income countries. This Notice encourages investigators with expertise and insight into the areas of global oncology and global health technology research and development to begin developing responsive applications.	Estimated post date: 3/1/22  Estimated proposal due date: 7/30/22	Up to \$475,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-031.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-031.html</a>
16.	Pre-Announcement: Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional) (NIH/NCI)	NOT-CA-22-041	This FOA will solicit applications for the Pediatric Immunotherapy Network (PIN). The purpose of this RFA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors.	Estimated post date: 3/31/22  Estimated proposal due date: 9/30/22	Up to \$450,000 per year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-041.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-041.html</a>
17.	Pre-Announcement: Dissemination and Implementation Research in Health (R01/R21 Clinical Trial Optional) (NIH/NCI)	NOT-CA-22-042 (R01)  NOT-CA-22-043 (R21)	These FOAs will support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.	Estimated post date: 5/8/22  Estimated proposal due date: 6/5/22 (R01)  Estimated proposal due date: 6/16/22 (R21)	Dependent upon proposal, for up to 5 years (R01)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-042.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-042.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-043.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-043.html</a> (R21)





	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>CANCER</b>			
18.	NOSI: Addressing Cancer-Related Financial Hardship to Improve Patient Outcomes (NIH/NCI)	NOT-CA-22-045	This notice invites research applications that propose to develop and/or test interventional approaches to prevent and/or mitigate financial hardship in individuals diagnosed with cancer. Intervention targets may include the patient, caregiver, clinician, healthcare team, and/or healthcare delivery system, with multi-level research encouraged. Proof of concept and studies testing the efficacy of interventions are acceptable; however, proposed studies should address the potential for intervention sustainability and scalability.	Multiple deadlines; first available due date: 4/1/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-045.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-045.html</a>
19.	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01/21 Clinical Trial Not Allowed) (NIH/NCI)	PAR-20-276 (R01) PAR-20-277 (R21)	These FOAs encourage applicants proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.	Proposal due: 2/5/22 6/5/22 (R01) Proposal due: 2/16/22 6/16/22 (R21)	Up to \$350,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-276.html">https://grants.nih.gov/grants/guide/pa-files/PAR-20-276.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-277.html">https://grants.nih.gov/grants/guide/pa-files/PAR-20-277.html</a> (R21)
20.	Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional/R21 Clinical Trial Not Allowed) (NIH/NCI)	PAR-20-281 (R01) PAR-20-282 (R21)	These FOAs support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health.	Letter of intent due: 9/19/22 5/19/23 Proposal due: 2/19/22 10/19/22 6/19/23	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-281.html">https://grants.nih.gov/grants/guide/pa-files/PAR-20-281.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-282.html">https://grants.nih.gov/grants/guide/pa-files/PAR-20-282.html</a> (R21)



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>CANCER</b>			
21.	Cancer Research Education Grants Program - Courses for Skills Development and Research Experiences (R25 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-278  PAR-21-279	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission. Three additional companion FOAs were listed in the Dec 2020 GBG report: PAR-21-065; 066; 067.	Proposal due: 5/25/22 9/25/22 1/25/23	Up to \$300,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-278.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-278.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-279.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-279.html</a>
22.	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01/R21 Clinical Trial Not Allowed) (NIH/NCI)	PAR-22-083 (R01)  PAR-22-084 (R21)	These FOAs seek applications focusing on epidemiologic research investigating emerging and new etiologic factors and liver cancer risk in populations relevant to the United States. Applications to this FOA should include, when possible, relevant biospecimens to evaluate associated risk factors and liver cancer risk. Applications that include an investigation on viral-associated liver cancer must provide strong rationale that outlines the added innovation or new knowledge to be gained from the current evidence of viral-associated liver cancer etiology. Appropriate research applications also include those that seek to understand the interplay of multiple factors that cause liver cancer across different U.S. populations.	Proposal due: 6/5/22 10/5/22 2/5/23 (R01)  Proposal due: 6/16/22 10/16/22 2/16/23 (R21)	Dependent upon proposal, for up to 5 years (R01)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-083.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-083.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-084.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-084.html</a> (R21)
23.	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) (NIH/NCI)	PAR-22-099	This FOA aims to encourage investigator-initiated research efforts aimed at the development, characterization and implementation of state-of-the-art biomimetic tissue-engineered technologies for cancer research as well as cancer diagnosis, treatment, and prevention strategies. Tissue-engineered in vitro and ex vivo systems that reflect the pathology and physiology of human disease are needed within the existing continuum of cancer models as new tools for understanding cancer biology.	Letter of intent due: 5/5/22 9/5/22 1/5/23  Proposal due: 6/5/22 10/5/22 2/5/23	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-099.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-099.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>CANCER</b>			
24.	Advanced Development and Validation of Emerging and Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61/R33 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-22-001 (R61)  RFA-CA-22-002 (R33)	RFA-CA-22-001 solicits R61 grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. RFA-CA-22-002 invites R33 grant applications where major feasibility gaps for the technology or methodology have been overcome, but further development and rigorous validation is required.	Letter of intent due: 3/22/22 8/22/22  Proposal due: 4/22/22 9/22/22	\$150,000 per year, for up to 3 years (R61)  \$300,000 per year, for up to 3 years (R33)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-001.html</a> (R61)  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-002.html</a> (R33)
25.	Innovative and Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33/61 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-22-003 (R61)  RFA-CA-22-004 (R33)	These FOAs solicit grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.	Letter of intent due: 3/22/22 8/22/22  Proposal due: 4/22/22 9/22/22	Up to \$150,000 per year, for up to 3 years (R61)  Up to \$300,000 per year, for up to 3 years (R33)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-003.html</a> (R61)  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-004.html</a> (R33)
			<b>CARDIOVASCULAR AND PULMONARY HEALTH (5)</b>			
26.	Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) (NIH/NHLBI)	RFA-HL-23-010	This Catalyze FOA solicits grant applications to rigorously validate transformative, multi-use platforms or technologies that can enable the next generation of predictive, diagnostic and therapeutic products or model systems relevant to heart, lung, blood and/or sleep (HLBS)-related diseases or disorders. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology.	Letter of intent due: 2/21/22 6/21/22 10/21/22  Proposal due: 3/21/22 7/21/22 11/21/22	Up to \$300,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-010.html</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>CARDIOVASCULAR AND PULMONARY HEALTH</b>			
27.	Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed) (NIH/NHLBI)	RFA-HL-23-011  RFA-HL-23-012	The Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop potential therapeutic candidates a lead compound series to identify potential therapeutics to treat HLBS diseases and disorders. Following successful completion of the program, it is expected that the lead compound series will be poised to move forward for preclinical testing with additional support from NIH and/or other federal and private programs. RFA-HL-23-011 supports early stage projects, RFA-HL-23-012 supports more advanced projects that have already completed the activities supported by the R61 phase of this initiative, but need continued support to identify a lead series.	Letter of intent due: 2/21/22 6/21/22 10/21/22  Proposal due: 3/21/22 7/21/22 11/21/22	Up to \$350,000 per year, for up to 3 years  Cost matching of at least 0.25:1 required for R33 grants	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-011.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html</a>
28.	Catalyze: Product Definition – Device Prototype Design, Testing, and Modification, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development and Validation (R61/R33 - Clinical Trial Not Allowed) (NIH/NHLBI)	RFA-HL-23-013  RFA-HL-23-014	The Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test/modify device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. Following successful completion of the program, it is expected that the lead compound series will be poised to move forward for preclinical testing with additional support from NIH and/or other federal and private programs. RFA-HL-23-013 supports early stage projects, RFA-HL-23-014 supports more advanced projects that have already completed the activities supported by the R61 phase of this initiative, but need continued support for continued development of their product.	Letter of intent due: 2/21/22 6/21/22 10/21/22  Proposal due: 3/21/22 7/21/22 11/21/22	Up to \$250,000 per year, for up to 3 years  Cost matching of at least 0.25:1 required for R33 grants	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-013.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>CHRONIC PAIN (1)</b>			
29.	Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) (NIH)	PA-18-939	This FOA encourages epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions.	Proposal due: 2/16/22	Up to \$275,000, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-939.html">https://grants.nih.gov/grants/guide/pa-files/pa-18-939.html</a>
			<b>COGNITIVE AND BRAIN HEALTH (25)</b>			
30.	Pre-Announcement: Peer Reviewed Alzheimer's Research Program (DoD/CDMRP)	N/A	Three awards are expected to be funded under PRARP in FY22. Applications submitted must address one or more of the following Focus Areas: <ul style="list-style-type: none"> <li>• Individual, caregiver, and family support</li> <li>• Environmental, Diagnostic, and Prognostic Factors</li> <li>• Fundamental research to better understand the etiology, risk, and comorbidities for AD/ADRD after TBI.</li> </ul>	TBD	Up to \$2.5 million, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/pubs/press/2022/22/prarppreann">https://cdmrp.army.mil/pubs/press/2022/22/prarppreann</a>
31.	Pre-Announcement: Epilepsy Research Program (DoD/CDMRP)	N/A	ERP expects to fund three awards in FY22. Applications must address one or more of the following Focus Areas: <ul style="list-style-type: none"> <li>• Innovative Research: Tools intended to better inform or improve upon PTE research and care</li> <li>• Markers and Mechanisms: Identifying biomarkers or mechanisms of PTE</li> <li>• Epidemiology: Epidemiological characterization of PTE following traumatic brain injury (TBI)</li> <li>• Longitudinal Studies: Studies of the evolution of PTE</li> </ul>	TBD	Up to \$1.3 million, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/pubs/press/2022/22/erppreann">https://cdmrp.army.mil/pubs/press/2022/22/erppreann</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>COGNITIVE AND BRAIN HEALTH</b>			
32.	Pre-Announcement: Autism Research Program (DoD/CDMRP)	N/A	<p>The ARP is expected to support research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD), via three awards in FY22. They include:</p> <ul style="list-style-type: none"> <li>• Clinical Trial Award: Supports research with the potential to have a major impact on the treatment/management of ASD</li> <li>• Idea Development Award: Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes</li> <li>• Career Development Award: Supports early-career investigators to conduct innovative, or early-phase, proof-of-principle clinical trials with the potential to have a major impact on ASD.</li> </ul>	TBD	<p>Up to \$2.1 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	<a href="https://cdmrp.army.mil/pubs/press/2022/22-arppreann">https://cdmrp.army.mil/pubs/press/2022/22-arppreann</a>
33.	Pre-Announcement: Amyotrophic Lateral Sclerosis Research Program (DoD/CDMRP)	N/A	<p>The ALSRP supports innovative and high-impact research into the development of effective treatments for ALS. Four different awards are anticipated for FY22:</p> <ul style="list-style-type: none"> <li>• Pilot Clinical Award: Supports exploratory clinical trials of novel therapeutics to demonstrate feasibility and inform the design of more advanced trials.</li> <li>• Therapeutic Development Award: Supports secondary preclinical validation and IND-enabling studies of therapeutics.</li> <li>• Clinical Biomarker Development Award: Supports maximization of clinical ALS resources and biorepositories to better define subtypes, predict therapeutic response, or assess prognosis.</li> <li>• Therapeutic Idea Award: Supports hypothesis-driven preclinical therapeutic development.</li> </ul>	TBD	<p>Up to \$2 million, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<a href="https://cdmrp.army.mil/pubs/press/2022/22-alsrpreann">https://cdmrp.army.mil/pubs/press/2022/22-alsrpreann</a>
34.	NOSI: Neuro-Glia Mechanisms Governing Complex Behaviors (NIH/NIMH)	NOT-MH-22-090	<p>This NOSI, with 7 linked grants, encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors. The influence of glial cell types on neural activity may explain behavioral processes across broad spatio-temporal scales and hierarchies. Discovering how mechanistic dysfunctions in neuro-glia interactions may alter behavioral phenotypes relevant to mental health is a challenge with potentially high translational impact.</p>	Multiple deadlines; first available due date: 6/5/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-090.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-090.html</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>COGNITIVE AND BRAIN HEALTH</b>			
35.	Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required) Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 – Clinical Trial Required) (NIH/NIA)	PAR-21-307 (R01)  PAR-21-308 (R61/R33)	The R01 FOA solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with AD and ADRD and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention’s principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions.	Letter of intent due: 9/11/22 1/10/23 9/10/22  Proposal due: 10/11/22 2/10/23 10/10/23	Dependent upon proposal, for up to 5 years (R01)  Up to \$500,000, for up to 2 years (R61)  Over \$500,000 per year, for up to 4 years (R33)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-307.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-307.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-308.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-308.html</a> (R61/R33)
36.	BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) (NIH)	RFA-MH-22-115	This FOA will support the phased development and validation of novel tools to facilitate the detailed analysis and/or manipulation of cells and circuits and provide insights into the neural circuitry and structure underlying complex behaviors in humans and non-human primates. Support will be provided for the initial development phase and can be continued through the validation and application phase if a rigorous set of milestones are achieved. For all tools and methods proposed, applicants should address issues related to safety stability, reliability and/or other relevant topics that may be barriers to adaptation in human or non-human primate brains.	Letter of intent due: 5/7/22 5/7/23 5/7/24  Proposal due: 6/7/22 6/7/23 6/7/24	Dependent upon proposal, for up to 8 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-115.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-115.html</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>COGNITIVE AND BRAIN HEALTH</b>			
37.	BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed) (NIH)	RFA-MH-22-145	The primary purpose of this FOA is to support the development of data standards that are needed to describe the new experiments generated by or used in the BRAIN Initiative. This is part of the program to build the informatics infrastructure for the BRAIN Initiative. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope. Awardees under all the informatics projects are expected to work together.	Letter of intent due: 5/14/22 5/14/23 5/14/24  Proposal due: 6/14/22 6/14/23 6/14/24	Dependent upon proposal, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-145.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-145.html</a>
38.	Neuromod Prize (NIH)		The Neuromod Prize is a SPARC initiative from the NIH that is accelerating the development of targeted neuromodulation therapies. The proposed solution should be tunable, accurate, and precise, and should demonstrate an ability to quantitatively assess and control multiple on-target and related off-target effects.	Concept paper due: 4/28/22	Up to \$800,000	<a href="https://www.neuromodprize.com">https://www.neuromodprize.com</a>
			<b>CORONAVIRUS (22)</b>			
39.	NOSI: Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment (NIH/NEI)	NOT-EY-22-010	This NOSI, with 12 linked grants, encourages researchers to leverage existing partnerships and build new partnerships with key stakeholders to develop and implement specific, targeted approaches for home-based testing strategies for people with visual impairment. Strategies should be scalable, sustainable, and consider the multiple stakeholders.	Multiple deadlines; first available due date: 3/7/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-EY-22-010.html">https://grants.nih.gov/grants/guide/notice-files/NOT-EY-22-010.html</a>
40.	NOSI: Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy (NIH/NHLBI)	NOT-HL-23-003	This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or comorbidities that predispose patients to CAC is also of interest.	Proposal due: 6/5/22 10/5/22 2/5/23	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-003.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-003.html</a>





	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>CORONAVIRUS</b>			
41.	NOSI: Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations (NIH)	NOT-MH-21-330	There are six opportunities listed within this NOSI, which highlights interest in research to strengthen the understanding and response to the COVID-19 pandemic and help us prepare more effectively for future public health emergencies. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects.	Multiple deadlines; first available due date: 6/5/22	Dependent on proposal and award, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-330.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-330.html</a>
42.	Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required/ Optional) (NIH/NIMH)	PAR-22-112 PAR-22-113	These FOAs aim to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic. All research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting health disparities.	Letter of intent due: 3/25/22 7/25/22 11/23/22 Proposal due: 4/25/22 8/25/22 12/23/22	Up to \$750,000 per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-112.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-112.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-113.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-113.html</a>
43.	Evaluating the Impact of COVID-19 Pandemic-related Food and Housing Policies and Programs on Health Outcomes in Health Disparity Populations (R01 Clinical Trial Optional) (NIH)	RFA-NR-22-001	The research objective is to use a natural experiment approach to examine how food and housing policies and programs that aimed to lessen the impact of the pandemic affected health and health equity, to understand the pathways of these effects, and to describe the long-term consequences. This FOA is intended to fund the study of natural experiments where an exposure or change is not directly manipulated by the researcher, and where comparable control data are available and confounding variables can be limited through study design, sample selection, and statistical analysis.	Letter of intent due: 3/7/22 Proposal due: 4/7/22	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-22-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-22-001.html</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>DARPA (4)</b>			
44.	Biological Technologies BAA (DoD/DARPA)	HR001121 S0025	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the DoD and addresses national security priorities. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biodefense	Abstracts & proposals accepted on a rolling basis until 4/22/22	Dependent upon proposal	<a href="https://sam.gov/opp/dfe93a5637fc419a8ea392ee949f9c79/view">https://sam.gov/opp/dfe93a5637fc419a8ea392ee949f9c79/view</a>
45.	Redefining Possible (DoD/DARPA)	HR001121 S0029	The Tactical Technology Office (TTO) of the Defense Advanced Research Projects Agency (DARPA) is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. The mission of the Tactical Technology Office (TTO) is to redefine access and delivery of effects to every domain in the battlespace: space, air, ground, sea, and undersea in support of national security policy.	Proposals accepted on a rolling basis until 6/10/22	Up to \$1 million, for up to 18 months	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334117">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334117</a>  (Full announcement in Related Documents tab)
46.	Defense Sciences Office, Office-wide (DoD/DARPA)	HR001121 S0032	The mission of the DARPA Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: (1) Frontiers in Math, Computation and Design, (2) Limits of Sensing and Sensors, (3) Complex Social Systems, and (4) Anticipating Surprise. Each of these thrust areas is described below and includes a list of example research topics that highlight several (but not all) potential areas of interest. Proposals must investigate innovative approaches that enable revolutionary advances.	Abstracts accepted on a rolling basis until 6/10/22	Dependent upon proposal	<a href="https://sam.gov/opp/f08ce40db929467ab7a8cdac02345b70/view">https://sam.gov/opp/f08ce40db929467ab7a8cdac02345b70/view</a>  (Full announcement in Related Documents tab)



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>DIAGNOSTICS (4)</b>			
47.	Microfluidics/ Lab-on-a-Chip/ Microchip-Based Point-of-Care Technologies (POCTRN)	N/A	The ACME POCT priority for the 2022 call for applications is to fund clinically relevant microfluidics- and/or microsensor-based proposals for technologies that have already been through some level of investment in research, development, evaluation, or clinical validation but have been unable to progress due to a significant and definable barrier that can be resolved through additional funds and/or targeted engineering, regulatory, clinical or other type of specific expertise the project team lacked.	Expression of Interest due: 2/28/22	Up to \$100,000, for 1 year	<a href="https://www.poctrn.org/web/acme-poct/solicitations">https://www.poctrn.org/web/acme-poct/solicitations</a>
48.	Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Disorders (POCTRN)	N/A	The CAPCaT announces the 2022 solicitation of grant applications focused on developing, adapting, or validating point of care technologies that can be rapidly applied to HLBS disorders, with additional interest in projects that incorporate complementary and integrative health approaches. CAPCaT is particularly interested in the development of disease diagnostics and monitoring devices, wearable technologies, mobile applications, and other tools to improve HLBS health in historically underserved, low-resource, and remote communities.	Expression of Interest due: 2/28/22	Up to \$100,000, for 1 year	<a href="https://www.poctrn.org/web/capcat/solicitations">https://www.poctrn.org/web/capcat/solicitations</a>
49.	Point-of-Care Technologies for HIV/AIDS in Low- and Middle-Income Countries (POCTRN)	N/A	C-THAN seeks to support projects designed for settings with limited medical infrastructure including restricted access to electricity, refrigeration and/or central water supply. Relevant projects considered for funding include, but are not limited to, diagnostic assays or technologies for HIV/AIDS disease and its comorbidities, treatment-related diagnostics, technologies that can be self-administered for either diagnosis or treatment monitoring, and/or technologies that improve or enable POC test performance.	Expression of Interest due: 2/28/22	Up to \$100,000, for 1 year	<a href="https://www.cimit.net/web/c-than/solicitations">https://www.cimit.net/web/c-than/solicitations</a>
50.	Improvements to Rapid Simple Point-of-Care Tests (POCT) for Sexually Transmitted Diseases (STDs) (POCTRN)	N/A	While the types of POC technologies considered will include both novel detection technologies and novel enabling technologies, this solicitation is seeking primarily to provide “tactical” funding to develop or improve on novel detection technologies. Preference in this solicitation is given to tests which definitively diagnose syphilis or discriminate syndromically related treatable STDs such as <i>Chlamydia trachomatis</i> , <i>Trichomonas vaginalis</i> , <i>Neisseria gonorrhoeae</i> , or <i>Mycoplasma genitalium</i> . Assays which can detect active Syphilis infections are particularly of interest.	Expression of Interest due: 2/28/22	Up to \$100,000, for 1 year	<a href="https://www.poctrn.org/web/jhu/funding-opportunity-2022">https://www.poctrn.org/web/jhu/funding-opportunity-2022</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>DISABILITIES (1)</b>			
51.	Rehabilitation Engineering Research Centers (RERC) Program: RERC on Rehabilitation Strategies, Techniques, and Interventions (HHS/ACL)	HHS-2022-ACL-NIDILRR-REGE-0024	NIDILRR-sponsored RERCs engage in the systematic application of engineering sciences to design, develop, adapt, test, evaluate, apply, and distribute technological solutions to problems confronted by people with disabilities in functional areas. In the area of rehabilitation strategies, techniques, and interventions, NIDILRR seeks to fund a RERC that leads to rehabilitation practices, services, or products that improve the health, physical, cognitive, sensory, or communication abilities, of people with a wide range of disabilities. Research and development topics under this priority may include but are not limited to: Robotics and automation technologies; virtual reality; telerehabilitation; recreational technology; health related products and equipment; and cognitive, sensory, and communication aids.	Proposal due: 3/28/22	Up to \$925,000 per year, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334811">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334811</a>
			<b>ENDOCRINE AND METABOLIC DISEASES (2)</b>			
52.	Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) (NIH/NIDDK)	PAR-22-111	The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies.	Letter of intent due: 6/14/22 10/14/22 6/14/23  Proposal due: 7/14/22 11/14/22 7/14/23	Up to \$500,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html</a>
53.	Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional) (NIH/NIDDK)	RFA-DK-22-005	This FOA invites investigator-initiated applications proposing broad basic, translational, and clinical studies and development of new measures, tools, treatments, and analytic approaches designed to address critical questions of pain as a component of diabetic neuropathy; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases.	Letter of intent due: 4/17/22  Proposal due: 5/17/22	Up to \$750,000 per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-005.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>ENERGY SCIENCE (1)</b>			
54.	FY 2022 Continuation of Solicitation for the Office of Science Financial Assistance Program (DoE)	DE-FOA-0002562	This BAA seeks proposals in multiple areas, including Biological and Environmental Research. By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio, including improved biofuels, bioproducts and biomaterials, improved carbon storage capabilities, and improved understanding of the biological cycling and transformation of nutrients, materials, and contaminants in the environment.	Proposals accepted on a rolling basis through 9/30/22	Dependent upon award mechanism	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=335970">https://www.grants.gov/web/grants/view-opportunity.html?oppld=335970</a>  (Full Announcement under Related Documents tab)
			<b>ENVIRONMENTAL HEALTH (1)</b>			
55.	Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional) (NIH/NIEHS)	RFA-ES-22-002	The NIEHS RIVER program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their independent environmental health sciences research program.	Letter of intent due: 5/9/22  Proposal due: 6/9/22	Up to \$600,000 per year, for up to 8 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-22-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-22-002.html</a>
			<b>GENOMICS (2)</b>			
56.	NHGRI Short Courses for Genomics-Related Research Education (R25 Clinical Trial Not Allowed) (NHGRI)	PAR-22-095	Proposed short courses are expected to facilitate the development of scientists with the requisite research skills to advance the mission of NHGRI. Applications are encouraged that propose innovative, advanced-level courses that are intended to disseminate new knowledge, approaches, methods and techniques related to the scientific, medical, ethical, social and/or legal areas of genomics research. In addition to in-person instruction, courses that incorporate innovative or novel education models, such as project-based learning or virtual instruction, are encouraged.	Letter of intent due: 12/24/22 12/24/23 12/24/24  Proposal due: 1/25/23 1/25/24 1/25/25	Up to \$150,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-095.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-095.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>GENOMICS</b>			
57.	Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 CT Not Allowed) (NIH/NHGRI)	RFA-HG-22-004	The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research.	Letter of intent due: 6/1/22 6/1/23  Proposal due: 7/1/22 7/1/23	Up to \$350,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-004.html</a>
			<b>GLOBAL HEALTH (2)</b>			
58.	FY2022 Development Innovation Ventures (USAID)	APS-7200AA22 APS00001	Through a year-round grant competition, DIV sources proposals for innovations that address international development challenges and improve the lives of people living in poverty in developing countries around the world. DIV provides tiered funding to pilot, test, and transition to scale those innovations that demonstrate evidence of impact, cost-effectiveness, and the potential to scale. DIV partners with innovators to save lives, reduce poverty, strengthen democracies, respond to climate change, mitigate the consequences of COVID-19, help people emerge from humanitarian crises, and more.	Proposals accepted on a rolling basis until 10/31/22	Up to \$15 million, dependent on proposal and availability of funds	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=336301">https://www.grants.gov/web/grants/view-opportunity.html?oppId=336301</a>  Full announcement under Related Documents tab
59.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH-BAA-2018	This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.	Expression of Interest accepted on a rolling basis though 5/30/22	Dependent upon proposal and award type	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=305999">https://www.grants.gov/web/grants/view-opportunity.html?oppId=305999</a>  (Full announcement in Related Documents tab)
			<b>HEALTH IT (51)</b>			
60.	State Vital Statistics Improvement Program (HHS/CDC)	CDC-RFA-SH22-2201	The purpose of this program is to improve the performance of the National Vital Statistics System by convening state vital statistics programs to evaluate and promote strategies for improving data quality, timeliness and utility for public health use; train and develop the vital statistics workforce; support accreditation of state vital statistics programs; and provide technical assistance.	Proposal due: 5/7/22	Up to \$720,000 per year, for 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=333926">https://www.grants.gov/web/grants/view-opportunity.html?oppId=333926</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>HEALTH IT</b>			
61.	Real-Time Assessment and Augmentation of Cognitive Performance in Extreme Environments (DoD/Air Force)	FA8650-22-S-5006	The primary focus of this effort is to develop wearable systems to continuously monitor biometrics of fatigue and stress using electrophysiological (EEG/EMG/EOG) modalities and biomarkers of stress such as cortisol, DHEA-s, epinephrine, NPY, etc. in interstitial fluid (ISF). In conjunction with these primary sensing modalities of interest, technologies developed in this effort may include other metrics of stress such as heart rate (HR) and heart rate variability (HRV), SpO2, StO2, ScO2, respiration, core body temperature, blood pressure, facial feature extraction, etc. to enhance the accuracy and precision of the determination of fatigue and stress. The secondary focus of this effort is to develop wearable augmentation technologies to counter fatigue and stress while considering and addressing austere environmental challenges. Technologies to counter fatigue and environmental stressors may include noninvasive vagal nerve stimulation, transcranial direct current stimulation, appropriate chemical stimulants, etc. The technologies developed in this effort should demonstrate at least TRL 5 level maturity at completion.	White paper due: 2/28/22	Up to \$23 million, for up to 5 years. 1:1 cost share required.	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=337373">https://www.grants.gov/web/grants/view-opportunity.html?oppId=337373</a>
62.	NOSI: Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research (NIH)	NOT-CA-22-037	Research supported by the 33 grants linked in this NOSI is expected to provide support for validation of recently developed digital health and AI technologies. Digital health and AI technologies are defined broadly to include any health technology leveraging mobile health, health information technology, wearable devices, sensors, telehealth and telemedicine, internet of things (IoT), software as a medical device (SaMD) and/or related AI algorithms and tools to monitor and manage health across the life course.	Multiple deadlines; first available due date: 3/7/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-037.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-037.html</a>
63.	NOSI: Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies (NIH/NIGMS)	NOT-GM-22-021	This NOSI, with 14 linked grants, aims to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is particularly interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the effects of possible intervention strategies, that include consideration of economic influences and feedback.	Multiple deadlines; first available due date: 3/7/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-GM-22-021.html">https://grants.nih.gov/grants/guide/notice-files/NOT-GM-22-021.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>HEALTH IT</b>			
64.	Pre-Announcement: Building Mathematical Modeling Workforce Capacity to Support Infectious Disease and Healthcare Research (CDC/ERA)	RFA-CK-22-008	This FOA will support pre-doctoral fellows' innovative research to develop and apply computational tools and mathematical methods for modeling the spread of pathogens in healthcare settings, antimicrobial resistant organisms [AROs]). This NOFO is intended to increase the number of junior modeling professionals that are trained and experienced in modeling transmission of pathogens in healthcare settings and to contribute to generalizable scientific knowledge through dissemination.	Estimated post date: 3/4/22  Estimated proposal due date: 5/4/22	Up to \$300,000	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=337897">https://www.grants.gov/web/grants/view-opportunity.html?oppId=337897</a>
65.	HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed) (NIH)	RFA-DE-22-011	This FOA will fund meritorious applications that analyze existing data and resources from humans, including large, diverse national research cohorts, to answer specific questions about the development of human acute or chronic pain and its management. This FOA may be used to test hypotheses using existing data. Applications may be related to, but must be distinct from, the specific aims of the original data collection.	Letter of intent due: 3/1/22  Proposal due: 3/31/22	Up to \$275,000, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-011.html</a>
			<b>HIV/AIDS (1)</b>			
66.	NOSI: Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups (NIH/NHLBI)	NOT-HL-22-010	This NOSI encourages applications to perform research that will advance our understanding of barriers to care and other risk factors that contribute to HIV-associated comorbidities among disproportionately affected population groups including gay, bisexual, and other men who have sex with men, in particular Black, Latino, and American Indian/Alaska Native men; Black women; transgender women; reproductive aged-women, people in the 13–24 year age group; and people who inject drugs.	Proposal due: 5/7/22 9/7/22 1/7/23	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-010.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-010.html</a>





	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (6)</b>			
67.	Antimicrobial Resistance Project BioShield: BARDA Antibiotic for AMR and Biothreat Pathogens (HHS/BARDA)	75A50122R00009	The United States Government seeks an antibiotic with marketing authorization for a bioterror indication for one or more of the following pathogen(s): <i>Y. pestis</i> , <i>F. tularensis</i> , or <i>B. pseudomallei</i> . Under this RFP, BARDA intends to use Project BioShield funds to support the late-stage development, approval, and potential procurement of an antibiotic. The anticipated contract award(s) includes completion of the regulatory pathway for a public health pneumonic indication and bioterror indication(s) as well as any efforts related to post-marketing commitments/requirements.	Proposal due: 4/6/22	Dependent upon proposal	<a href="https://sam.gov/opp/dc1a1411637d44e28898e36a99fd6fcf/view">https://sam.gov/opp/dc1a1411637d44e28898e36a99fd6fcf/view</a>
68.	Armed Forces Pest Management Board (DoD/AFPMB)	AFPMB-BAA-22-01	The AFPMB is soliciting pre-proposals for original and innovative research designed to develop new interventions for protection of deployed military personnel from diseases caused by arthropod-borne pathogens and to improve control of bed bugs and filth flies. Diseases of significant concern include Lyme disease, malaria, dengue fever and other arboviruses. The program supports development of: (1) new toxicants or the adaptation of existing toxicants to medically relevant pests; (2) new insecticide application techniques; (3) new personal protection tools that prevent human-vector contact; (4) decision support tools and (5) novel vector surveillance tools that focus on improved control outcomes.	White papers accepted on a rolling basis until 10/30/24	Up to \$900,000	<a href="https://sam.gov/opp/4fa92ea106a84436bce4c20cb6627e23/view">https://sam.gov/opp/4fa92ea106a84436bce4c20cb6627e23/view</a>
69.	Nonhuman Primate Transplantation Tolerance Cooperative Study Group (U01/U19 Clinical Trial Not Allowed) (NIH/NIAID)	RFA-AI-22-002 (U01) RFA-AI-22-003 (U19)	These FOAs solicit applications for the Nonhuman Primate Transplantation Tolerance Cooperative Study Group (NHPCSG), a multi-center, cooperative program dedicated to developing, optimizing, and evaluating approaches to induce and maintain immune tolerance to allogeneic transplants in nonhuman primate (NHP) models. The over-arching goal is to facilitate clinical translation of safe and effective tolerance-induction protocols for long-term graft survival.	Letter of intent due: 4/13/22 Proposal due: 5/13/22	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-002.html</a> (U01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-003.html</a> (U19)



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE</b>			
70.	ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers and Coordinating Center (U01 Clinical Trial Not Allowed) (NIH/NHLBI/NIGMS)	RFA-HL-23-001  RFA-HL-23-002	These FOAs establish the APS Consortium, which will seek to understand the heterogeneity and underlying mechanisms of critical illness syndromes and recovery, specifically in adults with ARDS, pneumonia, and/or sepsis, as well as the relationship and biological overlap among these syndromes. This will be accomplished through a prospective, longitudinal observational study with common data and biospecimen collection of 5,000 adults hospitalized in the United States with one or more of the following diagnoses: ARDS, pneumonia, or sepsis.	Letter of intent due: 5/17/22  Proposal due: 6/17/22	Up to \$2.075 million, for up to 6 years (Clinical Ctr)  Up to \$7.35 million, for up to 6 years (Coordinating Ctr)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-001.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-002.html</a>
			<b>MATERNAL AND PEDIATRIC HEALTH (7)</b>			
71.	Catalyst for Infant Health Equity (HHS/HRSA)	HRSA-22-066	The goals of this program are twofold: 1) to continue reducing overall infant mortality (IM) rates in the United States, and 2) to decrease and ultimately eliminate disparities in IM across racial/ethnic groups by achieving steeper declines for groups with the highest rates. To accomplish these goals, award recipients are expected to address the broader social and structural determinants contributing to IM disparities at the county or jurisdiction level.	Letter of intent due: 2/18/22  Proposal due: 4/19/22	Up to \$500,000 per year, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334421">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334421</a>
72.	Pre-Announcement: State Maternal Health Innovation & Data Capacity Program (HHS/HRSA)	HRSA-22-149	This program is to link State MHI activities with AIM activities: enhance the quality, validity, and timeliness of maternal health data; implement innovative maternal health activities at the state level; and support implementation of AIM bundles and AIM data collection, review, analysis, and reporting.	Estimated post date: 3/29/22  Estimated proposal due date: 5/27/22	Up to \$1.5 million	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=337896">https://www.grants.gov/web/grants/view-opportunity.html?oppId=337896</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>MATERNAL AND PEDIATRIC HEALTH</b>			
73.	Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional) (NIH)	RFA-HD-22-024	This initiative will support the establishment of a sustainable infrastructure and interdisciplinary research to generate innovative approaches to mitigate maternal morbidity and mortality (PRAMM) related to infections and sepsis, that could be leveraged to address other leading causes of PRAMM. The initiative requires an emphasis on disparities research inclusive of age, geographic, socioeconomic, and racial/ethnic disparities, including people with disabilities. Cooperative agreements are expected to promote interdisciplinary collaborations, synergistic research projects and sharing of knowledge and progress between funded projects that encompass significant community partnership to achieve goals and objectives.	Letter of intent due: 3/18/22  Proposal due: 4/18/22	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-024.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-024.html</a>
74.	Integrative Research in Gynecologic Health (R01 Clinical Trial Optional) (NIH/NICHD/ORWH)	RFA-HD-23-006	The ultimate goal of the FOA is to improve human gynecologic health by fostering partnerships between experts in diverse fields of research and enabling enhanced knowledge and resource sharing across these lines of inquiry. The projects developed will allow a cost-effective and collaborative route to accelerated transfer of scientific knowledge from bench to bedside and back again. These projects will also encourage partnerships with investigators who have not yet applied their expertise to gynecologic research, thereby expanding the potential scientific insight and investigational toolkit available to these projects.	Letter of intent due: 3/18/22  Proposal due: 4/18/22	Up to \$499,999 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-006.html</a>
75.	Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01/R21 Clinical Trial Optional) (NIH)	RFA-NR-22-002 (R01)  RFA-NR-22-003 (R21)	The AIM initiative will support original intervention research focused on improving maternal health outcomes among women who experience persistent disparities through an integrated supportive care approach. AIM interventions must target the three domains of interest within the context of supportive care. Studies must incorporate a conceptual framework and examine the mechanisms by which integrated supportive care impacts severe maternal morbidity or mortality outcomes. Women should be recruited early in pregnancy, ideally during the antepartum period, and followed one-year postpartum. Maternal mortality and/or severe maternal morbidity is a required primary outcome.	Letter of intent due: 3/7/22  Proposal due: 4/7/22	Dependent upon proposal, for up to 5 years (R01)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-22-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-22-002.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-22-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-22-003.html</a> (R21)



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>MATERNAL AND PEDIATRIC HEALTH</b>			
76.	Pre-Announcement: Initiative to Reduce Postpartum Deaths Due to Drug Overdose (HHS/OASH)	WH-AST-22-003	OWH anticipates the availability of funds to support grants focusing on postpartum deaths due to drug overdose. OWH anticipates funding applications for projects designed to strengthen perinatal and postnatal support structures for women with substance use disorder (SUD) and reduce deaths during the perinatal and postpartum periods due to drug overdose. For the purposes of this initiative, maternal deaths due to overdose are defined as death in the perinatal or postpartum period due to SUD.	Estimated post date: 3/22/22  Estimated proposal due date: 6/1/22	Up to \$300,000 per year, for up to 3 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=337413">https://www.grants.gov/web/grants/view-opportunity.html?oppId=337413</a>
			<b>MEDICAL COUNTERMEASURES (1)</b>			
77.	BAA for Medical Chemical Biological Radiological and Nuclear (CBRN) Medical Countermeasure Efforts (DoD/MCS)	MCSBAA17-01	The medical CBRN countermeasures developed by the Joint Project Manager Medical Countermeasure Systems (JPM MCS) office directly support the current, near-term, and far-term challenges by providing the capability to prevent, diagnose and treat the effects of chemical, radiological and biological warfare agents. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Defense Biological Product Assurance Office.	Pre-proposals accepted on a rolling basis through 6/2/22  Proposal by invitation	Dependent upon proposal and award mechanism	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=335729">https://www.grants.gov/web/grants/view-opportunity.html?oppId=335729</a>  (Full announcement under Related Documents tab)
			<b>MENTAL HEALTH (70)</b>			
78.	NOSI: NIMH Priorities on Research on Aggression and Violence Against Others (NIH/NIMH)	NOT-MH-22-095	In this NOSI, with 53 linked grants, NIMH expresses interest in supporting research on violence and aggression as it relates to mental health, mental illness, or as it relates to HIV prevention and treatment. Despite the occurrence of aggressive and violent behaviors in mental illnesses and their adverse consequences on society, there is a paucity of knowledge relevant to the etiological, neural, and behavioral underpinning of aggression and treatment strategies. NIMH encourages basic neuroscience studies that will apply circuit level analyses with cell-type and projection-specific manipulations to examine how interconnected circuits that subserve cognitive function, impulsivity relevant to executive function, reward and motivation, memory, and social processing influence the expression of aggression.	Multiple deadlines; first available due date: 3/10/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-095.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-095.html</a>



	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>MENTAL HEALTH</b>			
79.	NOSI: COVID-19 Pandemic Mental Health Research (NIH/NIMH)	NOT-MH-22-100	NIMH is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic.	Multiple deadlines; first available due date: 2/21/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-100.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-100.html</a>
80.	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R01/R34 Clinical Trial Not Allowed) (NIH/NIMH)	PAR-21-316 (R01) PAR-22-082 (R34)	These FOAs encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research.	Letter of intent due: 5/5/22 9/5/22 1/5/23  Proposal due: 6/5/22 10/5/22 2/5/23 (R01)  Letter of intent due: 5/16/22 9/16/22 1/16/23  Proposal due: 6/16/22 10/16/22 2/16/23 (R34)	Dependent on proposal, for up to 5 years (R01)  Up to \$450,000, for up to 3 years (R34)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-316.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-316.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-082.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-082.html</a> (R34)



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>NATIONAL SCIENCE FOUNDATION (2)</b>			
81.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) (NSF)	NSF 22-551	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development.	Project pitches accepted on a rolling basis.  Submission window for invited proposals: 1/11/22 to 3/4/22	Up to \$256,000 for up to 1 year	<a href="https://beta.nsf.gov/funding/opportunities/small-business-innovation-research-program-phase-i-sbirsttr-phase-i">https://beta.nsf.gov/funding/opportunities/small-business-innovation-research-program-phase-i-sbirsttr-phase-i</a>
			<b>NATIONAL VIRTUAL BIOTECHNOLOGY LABORATORY (1)</b>			
82.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	NVBL is a consortium of National laboratories, taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks.	N/A	Dependent upon solicitation and proposal	<a href="https://science.osti.gov/nvbl">https://science.osti.gov/nvbl</a>
			<b>OFFICE OF NAVAL RESEARCH (2)</b>			
83.	FY21 Funding Opportunity Announcement (FOA) for the Office of Naval Research (ONR) Science, Technology, Engineering and Mathematics (STEM) Program (DoD/Navy)	N00014-21-S-F005	The Office of Naval Research (ONR) seeks a broad range of applications for augmenting existing and/or developing innovative solutions that directly maintain and/or cultivate a diverse, world-class Science, Technology, Engineering and Mathematics (STEM) workforce to maintain the U.S. Navy and Marine Corps' technological superiority. The goal of proposed efforts must provide solutions that establish, build, and/or maintain STEM educational pathways and workforce opportunities for diverse U.S. citizens directly relevant to ONR science and technology areas.	Proposals accepted on a rolling basis until 3/30/22	Dependent upon proposal	<a href="https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BA/2021/N00014-21-S-F005-Amendment-0002.ashx">https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BA/2021/N00014-21-S-F005-Amendment-0002.ashx</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>OFFICE OF NAVAL RESEARCH</b>			
84.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology (DoD/Navy)	N00014-22-S-B001	The Office of Naval Research (ONR), ONR Global, and Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWLs broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.	Proposals accepted on a rolling basis until 9/30/22	Dependent upon proposal	<a href="https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements">https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements</a>
			<b>ORTHOTICS AND PROSTHETICS (2)</b>			
85.	Pre-Announcement: Orthotics and Prosthetics Outcomes Research Program (DoD/CDMRP)	N/A	Two awards are expected to be funded under the FY22 OPORP. Applications must address one or more of the Strategic Goals: <ul style="list-style-type: none"> <li>• Optimize patient-specific technology prescription for the Warfighter/Veteran.</li> <li>• Optimize patient-specific rehabilitation regimens for the Warfighter/Veteran.</li> <li>• Support standardized assessment of patient outcomes related to prosthetics and orthotics.</li> </ul>	TBD	Up to \$8 million, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/pubs/press/2022/22oporppreann">https://cdmrp.army.mil/pubs/press/2022/22oporppreann</a>
			<b>PAIN MANAGEMENT (3)</b>			
86.	Pre-Announcement: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) (NIH/NINDS)	NOT-NS-22-070	This FOA will promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology.	Estimated post date: 2/11/22  Estimated proposal due date: 3/11/22	TBD	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-22-070.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-22-070.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>PAIN MANAGEMENT</b>			
87.	HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed) (NIH)	RFA-NS-22-018	The objectives of this FOA are to support multidisciplinary groups of researchers to conduct collaborative, team-based science utilizing cutting-edge technologies and approaches and large-scale, high throughput tissue and single-cell analysis on primary human tissues involved in human pain processing to: Elucidate and validate functional roles of human genes and cellular phenotypes underpinning the heterogeneity, pathogenesis, and susceptibility to specific pain conditions; Enable and accelerate the discovery and validation of condition/disease-specific human pain therapeutic targets with enhanced translational potential; Coordinate with the U24 Human Pain-associated Genes & Cells Data Coordination and Integration Center to harmonize and integrate growing bodies of information related to datasets generated by the U19 research programs.	Letter of intent due: 2/17/22 6/7/22 9/11/22  Proposal due: 3/17/22 7/7/22 10/11/22	Up to \$1.5 million per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-018.html</a>
88.	HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) (NIH)	RFA-NS-22-050	This FOA aims to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology.	Letter of intent due: 2/11/22 5/23/22 9/13/22  Proposal due: 3/11/22 6/23/22 10/13/22	Up to \$500,000 per year, for up to 2 years (UG3)  Up to \$1.5 million per year, for up to 3 years (UH3)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-050.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-050.html</a>
			<b>PATIENT-CENTERED RESEARCH (3)</b>			
89.	Engagement Award: Capacity Building -- April 2022 Cycle (PCORI)	N/A	The Engagement Award: Capacity Building funding opportunity aims to support projects that help communities increase their facility with and ability to participate across all phases of the PCOR/CER process.	Letter of intent due: 4/4/22  Proposal by invitation, due: 7/11/22	Up to \$250,000, for up to 2 years	<a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-april-2022-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-april-2022-cycle</a>





	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>PATIENT-CENTERED RESEARCH</b>			
90.	Engagement Award: Dissemination Initiative -- April 2022 Cycle (PCORI)	N/A	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring relevant PCORI-funded research findings to end users in ways that will command their attention and interest and encourage use of this information in their healthcare decision making.	Letter of intent due: 4/4/22 Proposal by invitation, due: 7/11/22	Up to \$250,000, for up to 2 years	<a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-april-2022-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-april-2022-cycle</a>
91.	Engagement Award: Stakeholder Convening Support -- April 2022 Cycle (PCORI)	N/A	The Engagement Award: Stakeholder Convening Support funding opportunity aims to support projects that include multi-stakeholder convenings, meetings, and conferences that align with PCORI's mission and facilitate expansion of PCOR/CER through collaboration around such efforts.	Letter of intent due: 4/4/22 Proposal by invitation, due: 7/11/22	Up to \$100,000, for up to 2 years	<a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-april-2022-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-april-2022-cycle</a>
			<b>RARE DISEASES (2)</b>			
92.	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03/R21 Clinical Trial Not Allowed) (NIH/NCATS/NICHD)	PAR-22-100 (R03)  PAR-22-101 (R21)	These FOAs invite researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.	Letter of intent due: 4/17/22 9/17/22 4/15/23  Proposal due: 5/17/22 10/17/22 5/15/23	Up to \$50,000 per year, for up to 2 years (R03)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-100.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-100.html</a> (R03)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-101.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-101.html</a> (R21)
			<b>SMALL BUSINESS DEVELOPMENT (2)</b>			
93.	NASA SBIR/STTP Program (NASA)		NASA's SBIR/STTP Program funds early or "seed" stage research and development that has commercial potential. The program provides equity-free funding at the earliest stages of company and technology development. Focus areas include: Life Support and Habitation Systems, Human Research and Health Maintenance, and In-Situ Resource Utilization. View the solicitations for the <a href="#">full list of focus areas</a> .	Proposal due: 3/9/22	Up to \$125,000, for up to 13 months	<a href="https://sbir.nasa.gov/solicitations">https://sbir.nasa.gov/solicitations</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>SUBSTANCE USE DISORDER (22)</b>			
94.	Pre-Announcement: Alcohol Health Services Research (R01 Clinical Trial Optional) (NIH/NIAAA)	NOT-AA-22-004	This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.	Estimated post date: 3/1/22  Estimated proposal due date: 6/1/22	Up to \$500,000	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-004.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-004.html</a>
95.	Pre-Announcement: Alcohol Health Services Research (R34 Clinical Trial Optional) (NIH/NIAAA)	NOT-AA-22-005	This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.	Estimated post date: 3/1/22  Estimated proposal due date: 6/1/22	Up to \$450,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-005.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-005.html</a>
96.	Pre-Announcement: Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) (NIH/NIAAA)	NOT-AA-22-006	The NIAAA intends to solicit applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.	Estimated post date: 3/1/22  Estimated proposal due date: 6/1/22	Up to \$500,000 per year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-006.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-006.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>SUBSTANCE USE DISORDER</b>			
97.	Pre-Announcement: Alcohol Treatment and Recovery Research (R34 Clinical Trial Required) (NIH/NIAAA)	NOT-AA-22-007	The NIAAA intends to solicit applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.	Estimated post date: 3/1/22  Estimated proposal due date: 6/1/22	Up to \$450,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-007.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-007.html</a>
98.	NOSI: Research to Prevent Drug Use, Misuse and Addiction (NIH/NIDA)	NOT-DA-23-001	NIDA is interested in theory-driven prevention science that spans intervention development and testing, as well as services research, including dissemination and implementation science studies. Research addressing critical developmental periods and transitions or targeting interventions to groups at increased risk of adverse outcomes is of priority. Intervention research may occur at any level, and across the lifespan.	Multiple deadlines; first available due date: 6/5/22	Dependent upon proposal and award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-001.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-001.html</a>
99.	Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) (NIH/NIDA)	PAR-22-027	This FOA supports pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues; 2) responses to emerging marijuana trends and topics related to the shifting policy landscape, related to imminent policy change; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities; 4) responses to unexpected and time-sensitive medical system issues; 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities that relate to drug abuse and access and provision of health care service; 6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies; 7) research examining how the COVID-19 pandemic has impacted drug markets and overdose risk.	Letter of intent due: 4/3/22 8/8/22 12/8/22  Proposal due: 5/3/22 9/8/22 1/8/23	Up to \$275,000, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>SUBSTANCE USE DISORDER</b>			
100.	Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat AUD and AAOD (U43/U44/UT1/UT2 Clinical Trial Optional) (NIH/NIAAA)	PAR-22-102 (U43/U44)  PAR-22-103 (UT1/UT2)	These FOAs support SBIR and STTR applications that propose the development of therapeutic agents for the treatment of AUD and/or AAOD. As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application.	Letter of intent due: 2/28/22 11/5/22 2/27/23  Proposal due: 3/28/22 12/5/22 3/27/23	Phase I: Up to \$1 million per year, for up to 2 years  Phase II: Up to \$1.5 million per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html</a> (U43/U44)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html</a> (UT1/UT2)
101.	Rigorous Evaluation of Community-Level Substance Use and Overdose Prevention Frameworks that Incorporate ACEs-Related Prevention Strategies (CDC/ERA)	RFA-CE-22-009	The CDC NCIPC is soliciting investigator-initiated research to conduct rigorous evaluation of prevention approaches implemented within communities that incorporate efforts to mitigate the harms of adverse childhood experiences (ACEs) and prevent future ACEs, while simultaneously aiming to prevent substance use and overdose.	Proposal due: 2/22/22	Up to \$831,250 per year, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=336230">https://www.grants.gov/web/grants/view-opportunity.html?oppId=336230</a>
102.	Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks and Pediatric Anesthesia Safety Initiative (U01 Clinical Trial Not Allowed) (FDA/CDER)	RFA-FD-22-023	This program aims to streamline the discovery and development process of new drug products for the treatment of pain and substance use disorders, and of new anesthetic drug products, and to bridge the scientific and clinical gaps to ensure the safe use of anesthetic and sedative agents in children for the benefit of the public health. The FDA seeks to meet these goals, in part, through a public-private partnership (PPP), involving multiple stakeholders.	Proposal due: 4/11/22	Up to \$800,000 per year, for 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-023.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-023.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>SUBSTANCE USE DISORDER</b>			
103.	Emergency Award HEAL Initiative: Developing and Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co- Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional) (NIH)	RFA-MH- 22-175  RFA-MH- 22-176	RFA-MH-22-175 aims to encourage research studies that will optimize existing evidence-based multi-component service delivery interventions by testing the relative contribution of constituent components to overall effectiveness. RFA-MH-22-176 will encourage research studies that will develop and optimize multi-component service delivery interventions that are un- or under-tested in people with opioid use disorder and co-occurring conditions. This research will seek to streamline service delivery packages so they only include components that drive clinical improvements for complex conditions.	Letter of intent due: 2/18/22  Proposal due: 3/18/22	Up to \$1.25 million per year, for up to 5 years (RFA-MH- 22-175)  Up to \$500,000 per year, for up to 4 years (RFA-MH- 22-176)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-175.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-175.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-176.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-176.html</a>
104.	HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required) (NIH)	RFA-NS- 22-037	This FOA solicits applications to develop, test, and implement novel, culturally-appropriate pain interventions and/or adapt, test and evaluate efficacy and effectiveness of existing pain interventions, in populations that disproportionately experience negative health outcomes. Desired outcomes of these interventions include reduction of pain and pain-related symptoms, and improvement in overall health outcomes, including function and quality of life. Interventions that target populations that experience health disparities with chronic pain in addition to at least one comorbid condition are of the highest priority.	Letter of intent due: 2/22/22  Proposal due: 3/22/22	Up to \$500,000 per year, for up to 2 years (R61)  Up to \$1 million per year, for up to 4 years (R33)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-037.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-037.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>SUBSTANCE USE DISORDER</b>			
105.	Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) (NIH)	RFA-TR-22-011	This FOA aims to support early-stage research to increase our knowledge of understudied proteins of the druggable proteome and enable the scientific community to identify and validate new targets for pain, opioid use disorder (OUD), and/or overdose (OD). These awards will support generation of preliminary data and tools around eligible understudied protein(s) identified by the HEAL Program with the intent of elucidating the function of these proteins in the context of pain, OUD and/or OD and obtaining sufficient preliminary data and/or research resources for subsequent R01 applications and/or drug discovery/development projects.	Letter of intent due: 2/13/22 8/7/22 5/7/23  Proposal due: 2/28/22 8/22/22 5/22/23	Up to \$275,000, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-011.html</a>
106.	Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed) (NIH)	RFA-TR-22-013	This FOA aims to support scientists with high-impact, outside the box ideas. Novel treatments for pain, opioid addiction, and overdose are crucial to addressing the ongoing opioid crisis. The development of new treatment strategies is made difficult by the extraordinary complexity of both pain and addiction, consisting of physical, emotional, and social components. As such, effective treatment will require highly innovative ideas. These transformative, boundary-pushing applications are often risky or at a stage too early to fare well in the traditional peer review process.	Letter of intent due: 2/13/22 8/7/22 5/7/23  Proposal due: 2/28/22 8/22/22 5/22/23	Up to \$500,000 per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-013.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>THERAPEUTICS (3)</b>			
107.	Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44/UT1/UT2 Clinical Trial Optional) (NIH/NIAAA)	PAR-22-102 (U43/U44)  PAR-22-103 (UT1/UT2)	These FOAs support SBIR/STTP applications from SBCs that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application.	Letter of intent due: 2/28/22 11/5/22 2/27/23  Proposal due: 3/28/22 12/5/22 3/27/23	Phase I: Up to \$1 million per year, for up to 2 years  Phase II: Up to \$1.5 million per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html</a> (U43/U44)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html</a> (UT1/UT2)
108.	In Vitro Based Approaches to Evaluate the Bioequivalence of Prospective Generic Rectal and Vaginal Products (U01) Clinical Trial Not Allowed (FDA/CDER)	RFA-FD-22-014	The objective of this work is to support the development of product characterization-based BE approaches for rectal and vaginal drug products, with a specific focus on product performance tests such as IVRT studies and biorelevant IVPT studies. It is anticipated that this research will correlate the physicochemical and structural attributes of rectal and vaginal semi-solid dosage forms with product performance, develop IVRT methods to incorporate bio-relevant considerations, and develop IVPT methods using rectal and vaginal mucosal membranes to support comparative product characterization-based BE approaches for semi-solid rectal and vaginal drug products.	Letter of intent due: 2/11/22  Proposal due: 3/31/22	Up to \$250,000 per year, for up to 4 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-014.html</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>TRANSLATIONAL SCIENCE (1)</b>			
109.	Pre-Announcement: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional) (NIH)	NOT-TR-22-014	The CTSA Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This new CCIA FOA will support phased awards to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are commo	Estimated post date: 3/31/22  Estimated proposal due date: 7/29/22	Up to \$650,000 per year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-22-014.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-22-014.html</a>
			<b>TUBEROUS SCLEROSIS COMPLEX (3)</b>			
110.	Pre-Announcement: Tuberos Sclerosis Complex Research Program (DoD/CDMRP)	N/A	Three awards are expected to be funded under the TSCRCP. The Exploration – Hypothesis Development Award; Idea Development Award; and Clinical Translational Research Award. Applications must address one or more of the following focus areas: <ul style="list-style-type: none"> <li>• Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological and behavioral interventions</li> <li>• Strategies for eradicating tumors or other pathogenic lesions associated with TSC and TSC-associated lymphangioliomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways and tumor microenvironment</li> <li>• Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures</li> </ul>	TBD	Up to \$1 million, for up to 3 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/pubs/press/2022/22/tscrppreann">https://cdmrp.army.mil/pubs/press/2022/22/tscrppreann</a>





	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>US AIR FORCE ACADEMY (1)</b>			
111.	Research Interests of the United States Air Force Academy (DoD/Air Force)	USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. Research would essentially reveal mechanisms of existing natural systems, methods to incorporate present biological materials in nature, or disclose new capabilities within existing systems and/or materials.	Proposals accepted on a rolling basis	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175">https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175</a>  (Full announcement in Related Documents tab)
			<b>US ARMY COMBAT CAPABILITIES DEVELOPMENT COMMAND (1)</b>			
112.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD/Army)	W911QY20 R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. This posting is not for a specific requirement - only to post the BAA solicitation so that interested parties can submit white papers and proposals for grants and other assistance agreements.	Proposals accepted on a rolling basis until 2/28/25	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285</a>  (Full announcement in Related Documents tab)
			<b>US ARMY RESEARCH INSTITUTE (2)</b>			
113.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD/Army)	W911NF-18-S-0005	Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.	Proposals accepted on a rolling basis until 4/29/23  Full proposal required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462">https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462</a>  (Full announcement in Related Documents tab)



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>US ARMY RESEARCH INSTITUTE</b>			
114.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD/Army)	W911NF-21-S-0007	The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. Domains of interest include 1) Personnel Testing & Performance, 2) Learning in Formal and Informal Environments, 3) Organizational Effectiveness and 4) Leader Processes and Measurement.	White papers accepted until 5/15/22  Proposals accepted until 8/4/22	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391">https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391</a>  (Full announcement in Related Documents tab)
			<b>US MILITARY ACADEMY (1)</b>			
115.	United States Military Academy Broad Agency Announcement (DoD/USMA)	W911NF-20-S-0008	This BAA identifies topics of interest to USMA departments, directorates, and research centers and institutes. The groups fund a modest amount of extramural research in certain specific areas, including Human Support Systems, Life Sciences, and Emerging Technologies. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932">https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932</a>  (Full announcement in Related Documents tab)
			<b>US NAVY (2)</b>			
116.	FY21 Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement (DoD/Navy)	N0042121S0001	The NAWCAD is interested in receiving proposals for research and development projects, which offer potential for advancement and improvement of NAWCAD operations. NAWCAD has identified the research needed to address the challenges, problems, and future technology needs of the Warfighter. Research Opportunity Areas of Interest: Artificial Intelligence/Machine Learning, Data Science & Visualization, Cyber, Quantum, Hypersonic Systems, Test and Evaluation Engineering, Avionics, Sensors & Electronic Warfare, Secure Communications & Networks, Warfare Analysis, Readiness & Sustainment, Materials & Aircraft Structures, Aeromechanics, Mechanical Systems, Power & Propulsion Systems, Human Systems, Support Equipment, & Systems Engineering.	White papers accepted on a rolling basis until 6/2/22  Proposal solicited by invitation	Dependent upon proposal	<a href="https://sam.gov/opp/3a0e0f16bedb42db830347d2c18fc9e9/view">https://sam.gov/opp/3a0e0f16bedb42db830347d2c18fc9e9/view</a>



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>US NAVY</b>			
117.	C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research, Cryogenics & Quantum (DoD/Navy)	N66001-21-S-4700	The Naval Information Warfare Center, Pacific (NIWC Pacific) is soliciting white papers and proposals in accordance with Federal Acquisition Regulation (FAR). Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. Accordingly, proposals selected for award are the result of full and open competition and fully compliant with PL 98-369, "The Competition in Contracting Act of 1984." This BAA is for procurement contracts (hereinafter referred to as contracts), grants, cooperative agreements, and other transactions. Proposed research should investigate unique and innovative approaches for defining and developing next generation integratable C4ISR capabilities and command suites.	White papers accepted on a rolling basis until 6/4/22	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334026">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334026</a>  (Full announcement in Related Documents tab)
			<b>USAMRDC EXTRAMURAL BAA (1)</b>			
118.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD/USAMRDC)	W81XWH18SBAA1	This BAA supports extramural R&D ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.	Pre-applications accepted until 9/30/22  Full proposal by invitation	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726">https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726</a>  (Full announcement in Related Documents tab)



	<b>Title (Agency)</b>	<b>Opp. Number</b>	<b>Description</b>	<b>Deadline</b>	<b>Funding Level</b>	<b>Link</b>
			<b>USSOCOM EXTRAMURAL R&amp;D (1)</b>			
119.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD/USAMRAA)	W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. Equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Projects may apply existing knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.	Proposals accepted through 7/31/23  Submission of a pre-proposal is required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754">https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754</a>  (Full announcement in Related Documents tab)
			<b>WARFIGHTER MEDICAL OPTIMIZATION DIVISION (1)</b>			
120.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD/Air Force)	FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.	White papers accepted on rolling basis until 4/30/26	Up to \$49 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332</a>  (Full announcement in Related Documents tab)

